Piperacillin Sodium

證據等級: L5

預測適應症: 0 個

Piperacillin Sodium: Drug Repurposing Evaluation — No TxGNN Prediction Available

One-Sentence Summary

Piperacillin Sodium is a broad-spectrum beta-lactam antibiotic (semisynthetic penicillin) widely used in clinical settings to treat serious bacterial infections, often formulated in combination with the beta-lactamase inhibitor tazobactam. The current Evidence Pack contains no TxGNN-predicted new indications for this drug, and critical data including mechanism of action details, package insert information, and license specifics are pending collection. As a result, this report serves primarily as a data-gap summary and pre-evaluation baseline; a full repurposing assessment cannot be completed at this stage.

Quick Overview

Item	Content
Original Indication	Bacterial infections (broad-spectrum antibiotic; confirmed from drug class knowledge)
Predicted New Indication	No prediction available
TxGNN Prediction Score	N/A
Evidence Level	N/A — No predicted indication to evaluate
Malaysia Market Status	✓ Marketed
Number of Registrations	6
Recommended Decision	Hold

Why Is a Prediction Not Yet Available?

Piperacillin Sodium is a broad-spectrum semisynthetic penicillin antibiotic. It inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), thereby blocking transpeptidation and ultimately causing bacterial cell lysis. It is most commonly co-administered with tazobactam (a beta-lactamase inhibitor) to extend its spectrum against beta-lactamase-producing organisms.

The TxGNN model relies on the drug’s presence and linkage within the biomedical knowledge graph to generate repurposing candidates. The absence of a DrugBank ID in this Evidence Pack (drugbank_id: null) most likely prevented the model from anchoring Piperacillin Sodium in the graph, which explains why predicted_indications is empty.

Additionally, piperacillin’s primary mechanism — targeting bacterial enzymes — has limited mechanistic overlap with non-infectious disease pathways, which may further reduce the likelihood of high-confidence repurposing signals. However, this cannot be confirmed without completing the DrugBank mapping and re-running the prediction pipeline.

Clinical Trial Evidence

Currently no related clinical trials are registered for a repurposing context, as no predicted indication has been generated by TxGNN.

Literature Evidence

Currently no related literature is available for evaluation, as there is no predicted indication to search against.

Malaysia Market Information

Six active registrations are recorded for Piperacillin Sodium in Malaysia. However, detailed license-level information (authorization numbers, product names, dosage forms, and approved indication text) was not returned in the current data pull. The table below reflects what is available:

Authorization Number	Product Name	Dosage Form	Approved Indication
Pending data	Pending data	Pending data	Pending data
Pending data	Pending data	Pending data	Pending data
Pending data	Pending data	Pending data	Pending data
Pending data	Pending data	Pending data	Pending data
Pending data	Pending data	Pending data	Pending data

Note: 6 registrations are confirmed as active in NPRA. Full license details should be retrieved via a targeted NPRA query or direct download from the NPRA product registry.

Safety Considerations

Please refer to the package insert for safety information. Formal safety data (key warnings, contraindications, and drug interactions) could not be retrieved in this evidence collection cycle and must be sourced from:

The NPRA-approved Malaysian package insert (product label PDF)
The DrugBank entry for Piperacillin / Piperacillin-Tazobactam (once DrugBank ID is mapped)

As a general class reference, penicillin-class antibiotics are commonly associated with hypersensitivity reactions (including anaphylaxis), Clostridioides difficile-associated diarrhea, and nephrotoxicity at high doses — but these must be formally confirmed from the package insert before any evaluation proceeds.

Conclusion and Next Steps

Decision: Hold

Rationale: The TxGNN model returned no predicted new indications for Piperacillin Sodium, most likely because the drug could not be anchored in the knowledge graph due to a missing DrugBank ID. Without a prediction, there is no repurposing candidate to evaluate, and all critical data layers (MOA, safety warnings, license details) remain incomplete.

To proceed, the following is needed:

DrugBank mapping: Resolve drugbank_id for Piperacillin Sodium (likely DB00319 for piperacillin or DB00728 for piperacillin/tazobactam) and re-run the TxGNN knowledge graph prediction pipeline
Package insert retrieval: Download and parse the NPRA-approved product label PDF to populate MOA, key warnings, and contraindications (addresses Data Gaps DG001 and DG002)
NPRA license detail query: Re-query the NPRA registry to retrieve full authorization numbers, product names, dosage forms, and approved indication text for all 6 registrations
Re-run Evidence Pack: Once DrugBank ID is resolved and the prediction pipeline re-executed, regenerate this Evidence Pack with populated predicted_indications before proceeding to clinical and literature evidence review

⚠️ This report is for research reference only and does not constitute medical advice. Any repurposing candidate identified must be validated through clinical studies before application.

Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.